

Mj Garcia

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8502873/publications.pdf>

Version: 2024-02-01

42
papers

991
citations

430874

18
h-index

454955

30
g-index

43
all docs

43
docs citations

43
times ranked

1193
citing authors

#	ARTICLE	IF	CITATIONS
1	Population Pharmacokinetic Analysis of Vancomycin in Patients with Hematological Malignancies. Antimicrobial Agents and Chemotherapy, 2005, 49, 4934-4941.	3.2	102
2	Population Pharmacokinetics of High-Dose Methotrexate in Children with Acute Lymphoblastic Leukaemia. Clinical Pharmacokinetics, 2006, 45, 1227-1238.	3.5	86
3	Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome. JACC: Heart Failure, 2018, 6, 928-936.	4.1	86
4	Influence of the Cytochrome P450 2B6 Genotype on Population Pharmacokinetics of Efavirenz in Human Immunodeficiency Virus Patients. Antimicrobial Agents and Chemotherapy, 2009, 53, 2791-2798.	3.2	65
5	Valproate population pharmacokinetics in children. Journal of Clinical Pharmacy and Therapeutics, 1999, 24, 73-80.	1.5	59
6	Population pharmacokinetics of caffeine in premature neonates. European Journal of Clinical Pharmacology, 1997, 52, 211-217.	1.9	52
7	Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. , 1999, 20, 233-240.		46
8	Population Pharmacokinetics of Lamotrigine with Data from Therapeutic Drug Monitoring in German and Spanish Patients with Epilepsy. Therapeutic Drug Monitoring, 2008, 30, 483-489.	2.0	43
9	Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. Journal of Clinical Pharmacy and Therapeutics, 1993, 18, 191-197.	1.5	42
10	Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients. Antimicrobial Agents and Chemotherapy, 2011, 55, 5314-5324.	3.2	42
11	Covariate Effects on the Apparent Clearance of Tacrolimus in Paediatric Liver Transplant Patients Undergoing Conversion Therapy. Clinical Pharmacokinetics, 2001, 40, 63-71.	3.5	40
12	Carbamazepine Population Pharmacokinetics in Children. Therapeutic Drug Monitoring, 1997, 19, 132-139.	2.0	31
13	Vancomycin Dosage Optimization in Patients with Malignant Haematological Disease by Pharmacokinetic/Pharmacodynamic Analysis. Clinical Pharmacokinetics, 2009, 48, 273-280.	3.5	27
14	Monitoring of Serum Levels of Imipramine and Desipramine and Individualization of Dose in Enuretic Children. Therapeutic Drug Monitoring, 1984, 6, 438-443.	2.0	26
15	Comparison of 1-Year Outcome in Patients With Severe Aorta Stenosis Treated Conservatively or by Aortic Valve Replacement or by Percutaneous Transcatheter Aortic Valve Implantation (Data from a Tj ETQq1 1 0.784314 rg86 /Overl		26
16	Pharmacokinetics of cefoxitin in patients with normal or impaired renal function. European Journal of Clinical Pharmacology, 1979, 16, 119-124.	1.9	24
17	Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with nonâ€Hodgkin's lymphoma. British Journal of Clinical Pharmacology, 2016, 82, 1517-1527.	2.4	24
18	Bayesian Forecasting in Paediatric Populations. Clinical Pharmacokinetics, 1996, 31, 325-330.	3.5	23

#	ARTICLE	IF	CITATIONS
19	Cholephilic characteristics of a new cytostatic complex of cisplatin with glycocholate (Bamet-R2). <i>Journal of Controlled Release</i> , 1999, 57, 161-169.	9.9	18
20	Predictive Performance of Two Phenytoin Pharmacokinetic Dosing Programs from Nonsteady State Data. <i>Therapeutic Drug Monitoring</i> , 1994, 16, 380-387.	2.0	12
21	Population Kinetics of Tobramycin in Neonates. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 202-208.	2.0	12
22	Efavirenzâ€rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients. <i>Aids</i> , 2008, 22, 2549-2551.	2.2	12
23	Pharmacokinetics of cefoxitin during haemofiltration. <i>European Journal of Clinical Pharmacology</i> , 1983, 25, 395-398.	1.9	11
24	Dosage programming of phenobarbital in neonatal seizures. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1993, 18, 267-270.	1.5	11
25	COMPARISON OF METHODS OF CARBAMAZEPINE DOSAGE, INDIVIDUALIZATION IN EPILEPTIC PATIENTS. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1988, 13, 375-380.	1.5	10
26	Effect of Sodium Valproate on Phenobarbital Serum Levels in Children and Adults. <i>Therapeutic Drug Monitoring</i> , 1986, 8, 416-420.	2.0	8
27	The influence of clinical and pharmacological factors on enuresis treatment with imipramine.. <i>British Journal of Clinical Pharmacology</i> , 1990, 30, 693-698.	2.4	8
28	Influence of length of treatment on the interaction between phenobarbital and phenytoin. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1992, 17, 49-50.	1.5	7
29	Puesta en marcha de un hospital de dÃa del Ãrea del corazÃn: anÃlisis de actividad, calidad y coste-efectividad en el primer aÃo de funcionamiento. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 130-137.	1.2	7
30	Population pharmacokinetics of imipramine in children. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 89-92.	1.9	6
31	Disposition of Cefoxitin in patients with ascites. <i>European Journal of Clinical Pharmacology</i> , 1981, 20, 371-374.	1.9	5
32	Influence of experimental renal impairment in the pharmacokinetics of cefoxitin after intravenous administration to rabbits. <i>International Journal of Pharmaceutics</i> , 1980, 5, 117-125.	5.2	3
33	Pharmacokinetics of cefoxitin administered by i.v. infusion to patients with a pleural effusion. <i>European Journal of Clinical Pharmacology</i> , 1984, 26, 389-392.	1.9	3
34	TDM OF THEOPHYLLINEâ€COMPLIANCE EVALUATION. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1988, 13, 273-280.	1.5	3
35	Population Pharmacokinetics of Valproic Acid in Pediatric and Adult Caucasian Patients. <i>Pharmaceutics</i> , 2022, 14, 811.	4.5	3
36	COMPARISON OF TWO METHODS IN THE ESTIMATION OF THE PHARMACOKINETIC PARAMETERS OF PHENYTOIN. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1990, 15, 225-231.	1.5	2

#	ARTICLE	IF	CITATIONS
37	Dosage optimization methods applied to imipramine and desipramine in enuresis treatment. Journal of Clinical Pharmacy and Therapeutics, 1992, 17, 55-59.	1.5	2
38	Population pharmacokinetics of phenobarbital in Caucasian patients with epilepsy. European Journal of Pharmaceutical Sciences, 2020, 153, 105484.	4.0	1
39	Pharmacokinetics of cefoxitin administered intramuscularly to rabbits with experimentally-induced renal impairment. Biopharmaceutics and Drug Disposition, 1981, 2, 205-213.	1.9	0
40	Theophylline Monitoring and Noncompliance in Chronic Bronchial Asthma. Drug Intelligence & Clinical Pharmacy, 1988, 22, 633-634.	0.4	0
41	Predictive Techniques Applied to Imipramine Therapeutic Drug Monitoring. DICP: the Annals of Pharmacotherapy, 1989, 23, 389-394.	0.2	0
42	Predictive ability of different analytical parameters in Mycophenolate Pharmacokinetics and dosing. Clinical Therapeutics, 2015, 37, e45.	2.5	0